RADGOCITABINE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H12N4O4
Molecular Weight	252.2267
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N

InChI

InChIKey=DCYBPMFXJCWXNB-JWIUVKOKSA-N

InChI=1S/C10H12N4O4/c11-3-5-8(16)6(4-15)18-9(5)14-2-1-7(12)13-10(14)17/h1-2,5-6,8-9,15-16H,4H2,(H2,12,13,17)/t5-,6+,8-,9+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C10H12N4O4
Molecular Weight	252.2267
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://investor.cyclacel.com/news-releases/news-release-details/cyclacel-pharmaceuticals-announces-fda-orphan-drug-designation | https://www.ncbi.nlm.nih.gov/pubmed/26523431 | https://www.ashclinicalnews.org/online-exclusives/sapacitabine-fails-to-meet-primary-endpoint-in-clinical-trial-of-older-aml-patients/https://www.ncbi.nlm.nih.gov/pubmed/22739266 | https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C82697 | https://www.cyclacel.com/research_programs_oncology_cyc682.shtml

CNDAC (TAK-109) is an analog of the nucleoside deoxycytidine with potential antineoplastic activity. CNDAC is incorporated into DNA and induces single-strand breaks, which are converted into double-strand breaks (DSBs) when cells go through a second S phase. This results in the cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis. Sapacitabine, a prodrug of CNDAC, is being developed by the US biotechnology company Cyclacel for the treatment of hemalogical cancers and solid tumors.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human herpesvirus 8 3 Target ID: CHEMBL612780 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17402726	Inhibitor 8504		0.13 µM [IC50]
DNA 282 Target ID: DNA Sources: https://www.ncbi.nlm.nih.gov/pubmed/22739266	Binding Agent 1076

C_max

Value	Dose	Analyte	Population
2.58 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933907/	125 mg single, oral dose: 125 mg route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.43 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933907/	125 mg 2 times / day steady-state, oral dose: 125 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
17.635 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933907/	325 mg single, oral dose: 325 mg route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.88 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933907/	325 mg 2 times / day steady-state, oral dose: 325 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
14.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933907/	375 mg single, oral dose: 375 mg route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
25.45 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933907/	425 mg single, oral dose: 425 mg route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.77 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933907/	475 mg single, oral dose: 475 mg route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.52 ng/mL EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-5392-0	67 mg/m² single, oral dose: 67 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.09 ng/mL EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-5392-0	90 mg/m² single, oral dose: 90 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
9.48 ng/mL EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-5392-0	120 mg/m² single, oral dose: 120 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.76 ng/mL EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-5392-0	160 mg/m² single, oral dose: 160 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.35 ng/mL EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-5392-0	220 mg/m² single, oral dose: 220 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.1 ng/mL EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-8219-0	40 mg/m² 1 times / day steady-state, oral dose: 40 mg/m² route of administration: Oral experiment type: STEADY-STATE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
581.1 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933907/	125 mg single, oral dose: 125 mg route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
774.7 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933907/	125 mg 2 times / day steady-state, oral dose: 125 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5009.125 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933907/	325 mg single, oral dose: 325 mg route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3437 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933907/	325 mg 2 times / day steady-state, oral dose: 325 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1671 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933907/	375 mg single, oral dose: 375 mg route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5894.5 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933907/	425 mg single, oral dose: 425 mg route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
536 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19933907/	475 mg single, oral dose: 475 mg route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.22 mg × h/L EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-5392-0	67 mg/m² single, oral dose: 67 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
24 mg × h/L EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-5392-0	90 mg/m² single, oral dose: 90 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
42.8 mg × h/L EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-5392-0	120 mg/m² single, oral dose: 120 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
32 mg × h/L EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-5392-0	160 mg/m² single, oral dose: 160 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
19.32 mg × h/L EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-5392-0	220 mg/m² single, oral dose: 220 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
11 mg × h/L EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-8219-0	40 mg/m² 1 times / day steady-state, oral dose: 40 mg/m² route of administration: Oral experiment type: STEADY-STATE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
4.36 h EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-5392-0	67 mg/m² single, oral dose: 67 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.21 h EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-5392-0	90 mg/m² single, oral dose: 90 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.38 h EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-5392-0	120 mg/m² single, oral dose: 120 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.15 h EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-5392-0	160 mg/m² single, oral dose: 160 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.28 h EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-5392-0	220 mg/m² single, oral dose: 220 mg/m² route of administration: Oral experiment type: SINGLE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.6 h EXPERIMENT https://link.springer.com/article/10.1007/s10637-006-8219-0	40 mg/m² 1 times / day steady-state, oral dose: 40 mg/m² route of administration: Oral experiment type: STEADY-STATE co-administered:	SAPACITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

PubMed

Title	Date	PubMed
The efficacy of sapacitabine in treating patients with acute myeloid leukemia.	2018-11	30222471
Sapacitabine in the treatment of acute myeloid leukemia.	2015	26523431
Sapacitabine for cancer.	2012-04	22329458

Patents

Sample Use Guides

In Vivo Use Guide

oral sapacitabine capsules

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:11:17 GMT 2025` Edited by `admin` on `Mon Mar 31 21:11:17 GMT 2025`
Record UNII	00M634HD2V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RADGOCITABINE

Official Name

English

2'-CYANO-2'-DEOXY-1-(.BETA.-D-ARABINOFURANOSYL)CYTOSINE

Preferred Name

English

radgocitabine [INN]

Common Name

English

CNDAC

Common Name

English

Radgocitabine [WHO-DD]

Common Name

English

TAS-109

Code

English

DEOXYCYTIDINE ANALOGUE TAS-109

Common Name

English

2(1H)-PYRIMIDINONE, 4-AMINO-1-(2-CYANO-2-DEOXY-.BETA.-D-ARABINOFURANOSYL)-

Systematic Name

English

4-AMINO-L-(2-CYANO-2-DEOXY-.BETA.-D-ARABINOFURANOSYL)- 2(1H)-PYRIMIDINONE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1557